Ignite Creation Date:
2024-05-05 @ 5:08 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00391079
Status:
COMPLETED
Last Update Posted:
2013-06-24
First Post:
2006-10-20
Brief Title:
Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS
Sponsor:
GW Pharmaceuticals Ltd
Organization:
GWPharm
Study Overview
Official Title:
A Double Blind Randomised Placebo Controlled Parallel Group Study of Sativex When Added to the Existing Treatment Regimen in the Relief of Central Neuropathic Pain in Subjects With Multiple Sclerosis
Status:
COMPLETED
Status Verified Date:
2013-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to find out if cannabis-based medicine compared to a dummy medicine placebo that contains no active ingredient can help the central neuropathic pain patients experience as a result of multiple sclerosis This type of pain central neuropathic pain is described as shooting stabbing burning or searing like sensation which is often worse at night
Detailed Description:
GW has shown in phase II and III studies that Sativex has analgesic properties that are effective in relieving neuropathic pain These studies suggested that Sativex is well tolerated and may also improve sleep and quality of life GW is conducting this study to further demonstrate these effects
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None